Fort Washington Investment Advisors Inc. OH Buys 177,546 Shares of Progyny, Inc. $PGNY

Fort Washington Investment Advisors Inc. OH grew its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 10.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 1,834,104 shares of the company’s stock after buying an additional 177,546 shares during the quarter. Fort Washington Investment Advisors Inc. OH’s holdings in Progyny were worth $47,100,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Federated Hermes Inc. raised its holdings in Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after buying an additional 819 shares during the last quarter. Versant Capital Management Inc grew its holdings in Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock worth $50,000 after acquiring an additional 894 shares during the last quarter. Covestor Ltd increased its position in shares of Progyny by 164.9% in the third quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after acquiring an additional 1,624 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Progyny in the second quarter valued at about $77,000. Finally, Quarry LP raised its stake in shares of Progyny by 2,004.1% during the third quarter. Quarry LP now owns 3,598 shares of the company’s stock valued at $77,000 after acquiring an additional 3,427 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PGNY shares. KeyCorp dropped their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a report on Monday, March 2nd. Canaccord Genuity Group lowered their price target on Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price objective on shares of Progyny in a report on Friday, March 6th. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, BTIG Research reduced their target price on Progyny from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Thursday, March 5th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.91.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the transaction, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. This represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 7,455 shares of company stock worth $129,515. 9.40% of the stock is currently owned by corporate insiders.

Progyny Trading Up 0.2%

Shares of PGNY opened at $17.79 on Friday. Progyny, Inc. has a 1-year low of $16.75 and a 1-year high of $28.75. The firm’s 50-day moving average price is $20.75 and its 200-day moving average price is $22.41. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 27.37, a PEG ratio of 1.02 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The company had revenue of $318.40 million during the quarter, compared to the consensus estimate of $314.26 million. During the same period in the prior year, the firm earned $0.42 earnings per share. Progyny’s revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.